A Single-Center, Open-Label, Phase II Study of Tislelizumab + SOX Regimen as a New Adjuvant Long-Course Treatment for Locally Advanced Gastric Cancer/Gastric Cardia Adenocarcinoma

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2024
This article has no abstract
Epistemonikos ID: 0dc51999e0b127e52bd85231cdfe17b22f17e8e6
First added on: Apr 08, 2025